Segall Bryant & Hamill LLC lowered its stake in Orthofix International NV (NASDAQ:OFIX) by 2.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 664,644 shares of the medical device company’s stock after selling 16,238 shares during the period. Orthofix International accounts for 0.9% of Segall Bryant & Hamill LLC’s portfolio, making the stock its 27th largest position. Segall Bryant & Hamill LLC’s holdings in Orthofix International were worth $39,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently modified their holdings of OFIX. SG Americas Securities LLC acquired a new stake in shares of Orthofix International in the first quarter valued at approximately $151,000. Meeder Asset Management Inc. boosted its stake in Orthofix International by 186.4% in the first quarter. Meeder Asset Management Inc. now owns 2,626 shares of the medical device company’s stock valued at $154,000 after acquiring an additional 1,709 shares during the last quarter. Quantbot Technologies LP bought a new position in Orthofix International in the first quarter valued at approximately $161,000. Ramsey Quantitative Systems bought a new position in Orthofix International in the fourth quarter valued at approximately $247,000. Finally, Crossmark Global Holdings Inc. bought a new position in Orthofix International in the fourth quarter valued at approximately $260,000. 91.78% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have issued reports on the stock. TheStreet raised shares of Orthofix International from a “c+” rating to a “b” rating in a research note on Tuesday, March 20th. BidaskClub raised shares of Orthofix International from a “hold” rating to a “buy” rating in a research note on Friday, March 16th. SunTrust Banks raised their price objective on shares of Orthofix International to $67.00 and gave the company a “buy” rating in a research note on Monday, March 5th. ValuEngine raised shares of Orthofix International from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, Gabelli reaffirmed a “buy” rating on shares of Orthofix International in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Orthofix International has a consensus rating of “Buy” and an average target price of $58.07.
Shares of NASDAQ OFIX traded down $0.26 during midday trading on Thursday, reaching $57.86. 820 shares of the stock were exchanged, compared to its average volume of 140,477. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of 35.88, a P/E/G ratio of 3.50 and a beta of 0.26. Orthofix International NV has a 12 month low of $42.68 and a 12 month high of $61.86.
Orthofix International (NASDAQ:OFIX) last announced its quarterly earnings results on Monday, April 30th. The medical device company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.03. The company had revenue of $108.71 million for the quarter, compared to analysts’ expectations of $107.10 million. Orthofix International had a net margin of 3.21% and a return on equity of 11.08%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $0.27 earnings per share. analysts forecast that Orthofix International NV will post 1.66 EPS for the current fiscal year.
Orthofix International Profile
Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.
Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix International NV (NASDAQ:OFIX).
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.